This Week in Pediatric Oncology
immunotherapy
Episodes
Thursday Oct 06, 2016
Thursday Oct 06, 2016
TWIPO hosts Dr. Timothy Cripe and Dr. Nilay Shah (Nationwide Children's Hospital) along with guest
host Dr. Ryan Roberts (Nationwide Children's Hospital), interview Dr. Elizabeth Lawlor who is a Professor of Pediatric
Oncology at University of Michigan and the Director of the Cancer Biology
Training Program at University of Michigan Health System. Dr. Lawlor, a Ewing Sarcoma specialist, discusses
new approaches to the cellular eco-system of tumors and provides commentary on the growing
landscape for women in science.
Tuesday Sep 06, 2016
Tuesday Sep 06, 2016
On today's podcast, TWIPO host Dr. Timothy Cripe (Nationwide Children’s Hospital) and co-host Dr. Ryan Roberts (Nationwide Children’s Hospital) interview Dr. Mark Hatley (St. Jude Children's Research Hospital). Dr. Hatley discusses how he got into the field of Biological Chemistry in Oncology. Also Dr. Hatley gives an indepth explaination about his research in G-Proteins.
Tuesday Nov 18, 2014
Tuesday Nov 18, 2014
In the most recent episode
of This Week in Pediatric Oncology, co-hosts Dr. Nilay Shah (Nationwide
Children’s Hospital), Dr. Timothy Cripe (Nationwide Children’s Hospital), and
Dr. Lionel Chow (Cincinnati Children’s) discuss the promising results of a
study published in the July issue of Journal
of Clinical Oncology among children with an aggressive brain tumor after receiving
immunotherapy. To see a summary of the study, click here.
Monday Feb 10, 2014
Monday Feb 10, 2014
May
07, 2012
In this interesting episode, host Dr. Tim Cripe
(Nationwide Children's) and co-hosts Dr. Lionel Chow (Cincinnati Children's),
Dr. Andy Kolb (AI DuPont), and Donna Ludwinski (Solving Kids' Cancer) quiz Dr
Paul Sondel and Dr. Ken DeSantes (both from University of Wisconsin - Madison)
on NK cells and the implications of KIR/KIR-ligand mismatch (killer
immunoglobulin-like receptor) with regard to immunotherapy treatment of
neuroblastoma.
References:
Delgado DC, Hank JA, Kolesar J, Lorentzen D, et
al. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the
response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res.
2010 Dec 1;70(23):9554-61. Epub 2010 Oct 8.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2999644/
.
Venstrom JM, Zheng J, Noor N, Danis KE, et al.
KIR and HLA genotypes are associated with disease progression and survival
following autologous hematopoietic stem cell transplantation for high-risk
neuroblastoma. Clin Cancer Res. 2009 Dec 1;15(23):7330-4. Epub 2009 Nov 24.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788079/
.
Alderson KL, Sondel PM. Clinical cancer therapy
by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed
Biotechnol. 2011;2011:379123. Epub 2011 May 24.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110303/